Valeo Financial Advisors LLC boosted its position in Eli Lilly and Co (NYSE:LLY) by 51.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 61,487 shares of the company’s stock after acquiring an additional 21,002 shares during the period. Eli Lilly and comprises approximately 0.9% of Valeo Financial Advisors LLC’s holdings, making the stock its 22nd biggest holding. Valeo Financial Advisors LLC’s holdings in Eli Lilly and were worth $5,193,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Gradient Investments LLC bought a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $103,000. Acrospire Investment Management LLC lifted its stake in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and during the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and during the second quarter valued at approximately $129,000. Finally, Front Row Advisors LLC acquired a new stake in Eli Lilly and during the fourth quarter valued at approximately $137,000. 77.58% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Donald A. Zakrowski sold 876 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total transaction of $67,933.80. Following the completion of the sale, the insider now owns 4,130 shares in the company, valued at approximately $320,281.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the sale, the senior vice president now owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. Insiders sold a total of 12,261 shares of company stock valued at $987,485 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $0.95 EPS. research analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
Several research firms recently commented on LLY. TheStreet lowered shares of Eli Lilly and from a “b” rating to a “c” rating in a research note on Monday, March 5th. Jefferies Group set a $93.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. set a $105.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Credit Suisse Group reiterated a “hold” rating and issued a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Finally, Bank of America cut their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $93.47.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.